Therapeutic Options for Middle East Respiratory Syndrome Coronavirus (MERS-CoV) - possible lessons from a systematic review of SARS-CoV therapy

International Journal of Infectious Diseases

Volumn 17, Issue 10, 2013, Pages

  Momattin, Hisham ^a   Mohammed, Khurram ^a   Zumla, Alimuddin ^b   Memish, Ziad A ^c   Al Tawfiq, Jaffar A ^a,d  

^a DHAHRAN HEALTH CENTER   (Saudi Arabia)

^b UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^c ALFAISAL UNIVERSITY   (Saudi Arabia)

^d INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Interferon; MERS CoV; Ribavarin; SARS

Indexed keywords

ANTIVIRUS AGENT; AZITHROMYCIN; CEFOTAXIME; CLARITHROMYCIN; CONSENSUS INTERFERON; HYDROCORTISONE; LEVOFLOXACIN; LOPINAVIR PLUS RITONAVIR; METHYLPREDNISOLONE; OSELTAMIVIR; PEGINTERFERON ALPHA2B; PREDNISOLONE; PREDNISONE; QUINOLONE; RIBAVIRIN;

ACUTE HEART INFARCTION; ADULT RESPIRATORY DISTRESS SYNDROME; ARTICLE; ARTIFICIAL VENTILATION; CONVALESCENCE; CORONAVIRUS; CORONAVIRUS INFECTION; COUGHING; DRUG EFFICACY; DRUG FEVER; DRUG MEGADOSE; DRUG SAFETY; DRY COUGH; DYSPNEA; EPIDEMIC; FOLLOW UP; HEMOLYSIS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; INTENSIVE CARE UNIT; LOADING DRUG DOSE; LYMPHOCYTOPENIA; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS INFECTION; PLASMA TRANSFUSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPIRATORY FAILURE; SARS CORONAVIRUS; SEPSIS; SEVERE ACUTE RESPIRATORY SYNDROME; SIDE EFFECT; SYSTEMATIC REVIEW; THERAPY DELAY; TREATMENT DURATION; TREATMENT RESPONSE; VIRUS REPLICATION;

INTERFERON; MERS-COV; RIBAVARIN; SARS;

ANTIVIRAL AGENTS; CORONAVIRUS INFECTIONS; HUMANS; INTERFERON-ALPHA; LOPINAVIR; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RITONAVIR; SARS VIRUS; SEVERE ACUTE RESPIRATORY SYNDROME; TREATMENT OUTCOME;

EID: 84883775193     PISSN: 12019712     EISSN: 18783511     Source Type: Journal    
DOI: 10.1016/j.ijid.2013.07.002     Document Type: Article

References (26)

1. AlBarrak A.M., Stephens G.M., Hewson R., Memish Z.A. Recovery from severe novel coronavirus infection. Saudi Med J 2012, 33:1265-1269.
2. CDC. Middle East Respiratory Syndrome. Available at: last accessed July 27, 2013. http://www.cdc.gov/coronavirus/mers/faq.html.
3. Assiri A., McGeer A., Perl T.M., et al. Hospital outbreak of Middle East respiratory syndrome coronavirus. N Engl J Med 2013, 369(5):407-416.
4. Assiri A., Al-Tawfi q J.A., Al-Rabeeah A.A., et al. Epidemiological, demographic, and clinical characteristics of 47 cases of Middle East respiratory syndrome coronavirus disease from Saudi Arabia: a descriptive study. Lancet Infect Dis 2013, published online July 26. http://dx.doi.org/10.1016/S1473-3099(13)70204-4.
5. Stockman L.J., Bellamy R., Garner P. SARS: systematic review of treatment effects. PLoS Med. 2006, 3:e343.
6. World Health Organization. Clinical management of severe acute respiratory infections when novel coronavirus is suspected: What to do and what not to do. Available at: http://www.who.int/csr/disease/coronavirus_infections/InterimGuidance_ClinicalManagement_NovelCoronavirus_11Feb13u.pdf.
7. U.S. Preventive Services Task Force (August 1989). Guide to clinical preventive services: report of the U.S. Preventive Services Task Force. DIANE Publishing. pp. 24. ISBN 978-1-56806-297-6.
8. Poutanen S.M., Low D.E., Henry B., Finkelstein S., Rose D., Green K., et al. Identification of severe acute respiratory Syndrome in Canada. N Eng J Med. 2003, 348:1995-2005.
9. Tsang K.W., Ho P.L., Ooi G.C., Yee W.K., Wang T., Chan-Yeung M., et al. A Cluster of Cases of Severe Acute Respiratory Syndrome in Hong Kong. N Eng J Med. 2003, 348:1977-1985.
10. Booth C.M., Matukas L.M., Tomlinson G.A., Rachlis A.R., Rose D.B., Dwosh H.A., et al. Clinical features and short-term outcomes of 144 patients with SARS in the greater Toronto area. JAMA. 2003, 290:334.
11. Hsu L.Y., Lee C.C., Green J.A., Ang B., Paton N.I., Lee L., et al. Severe acute respiratory syndrome (SARS) in Singapore: clinical features of index patient and initial contacts. Emerg Infect Dis. 2003, 9:713-717.
12. Peiris J.S., Chu C.M., Cheng V.C., Chan K.S., Hung I.F., Poon L.L., et al. Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study. Lancet. 2003, 361:1767-1772.
13. Zhao Z., Zhang F., Xu M., Huang K., Zhong W., Cai W., et al. Description and clinical treatment of an early outbreak of severe acute respiratory syndrome (SARS) in Guangzhou, PR China. J Med Microbiol. 2003, 52:715-720.
14. Sung J.J., Wu A., Joynt G.M., Yuen K.Y., Lee N., Chan P.K., et al. Severe acute respiratory syndrome: report of treatment and outcome after a major outbreak. Thorax 2004, 59:414-420.
15. Ooi C.G., Khong P.L., Ho J.C., Lam B., Wong W.M., Yiu W.C., et al. Severe Acute Respiratory Syndrome: Radiographic Evaluation and Clinical Outcome Measures. Radiology 2003, 229:500-506.
16. Leong H.N., Ang B., Earnest A., Teoh C., Xu W., Leo Y.S. Investigational use of ribavirin in the treatment of severe acute respiratory syndrome, Singapore, 2003. Trop Med Int Health. 2004, 9:923-927.
17. Chan K.S., Lai S.T., Chu C.M., Tsui E., Tam C.Y., Wong M.M., et al. Treatment of severe acute respiratory syndrome with lopinavir/ritonavir: a multicentre retrospective matched cohort study. Hong Kong Med J 2003, 9:399-406.
18. Chu C.M., Cheng V.C., Hung I.F., Wong M.M., Chan K.H., Chan K.S., et al. Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings. Thorax 2004, 59:252-256.
19. Yeh K.M., Chiueh T.S., Siu L.K., Lin J.C., Chan P.K., Peng M.Y., et al. Experience of using convalescent plasma for severe acute respiratory syndrome among healthcare workers in a Taiwan hospital. J Antimicrob Chemother. 2005, 56:919-922.
20. Burnouf T., Radosevich M. Treatment of severe acute respiratory syndrome with convalescent plasma. Hong Kong Med J. 2003, 9:309. author reply 310.
21. Cheng Y., Wong R., Soo Y.O., Wong W.S., Lee C.K., Ng M.H., et al. Use of convalescent plasma therapy in SARS patients in Hong Kong. Eur J Clin Microbiol Infect Dis. 2005, 24:44-46.
22. Soo Y.O., Cheng Y., Wong R., Hui D.S., Lee C.K., Tsang K.K., et al. Retrospective comparison of convalescent plasma with continuing high-dose methylprednisolone treatment in SARS Patients. Clin Microbiol Infect 2004, 10:676-678.
23. Loutfy M.R., Blatt L.M., Siminovitch K.A., Ward S., Wolff B., Lho H., et al. Interferon alfacon-1 plus corticosteroids in severe acute respiratory syndrome: a preliminary study. JAMA. 2003, 290:3222-3228.
24. Chan K.H., Chan J.F., Tse H., Chen H., Lau C.C., Cai J.P., et al. Cross-reactive antibodies in convalescent SARS patients' sera against the emerging novel human coronavirus EMC (2012) by both immunofluorescent and neutralizing antibody tests. J Infect. 2013, 67:130-140.
25. ISARIC, International Severe Acute Respiratory & Emerging Infection Consortium. Clinical Decision Making Tool for Treatment of MERS-CoV v.1.0, 18 June, 2013. Available at: last accessed July 26, 2013. http://www.hpa.org.uk/webc/HPAwebFile/HPAweb_C/1317139281416.
26. Raj V.S., Mou H. Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC. Nature. 2013, 495:251-254.